Additionally, glyceollin inhibits the growth of LNCaP prostate cancer cells through targeting G1/S phase cell transition [30], long-term estrogen-deprived (LTED) MCF-7 breast cancer cells [31], estrogen-dependent aromatase-inhibitor-resistant T47DaromLR cells [11], and estrogen-independent LTLT-Ca cells [23]. Here, CYP19A1 is linked to prostate cancer.